According to a new report by RAND Corporation, biosimilars could save $54 billion in healthcare spending on biologics over the next ten years.[i] The report’s key findings include:

• The estimated cost savings potential of biosimilars is $54 billion over the next decade, or about 3% of total estimated biologic spending during the same period,

…